Clinical trials

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular…

Investigator

Francesco Franchi

Ages

40 Years - 79 Years

Sexes

All

INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to

Investigator

Brittany S Bruggeman

Ages

10 Years - 17 Years

Sexes

All